Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation

Leukemia and Lymphoma

Volumn 52, Issue 8, 2011, Pages 1455-1462

  Fenk, Roland ^a   Liese, Vanessa ^a   Neubauer, Florian ^a   Bruns, Ingmar ^a   Kondakci, Mustafa ^a   Balleisen, Sebastian ^a   Saure, Christian ^a   Schröder, Thomas ^a   Haas, Rainer ^a   Kobbe, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

autologous peripheral blood stem cell transplant; high dose therapy; Multiple myeloma; predictive factors; relapsed refractory

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; BORTEZOMIB; BUSULFAN; MELPHALAN; PALIFERMIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; DRUG DOSE REDUCTION; DRUG FATALITY; EVENT FREE SURVIVAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; BUSULFAN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79960428352     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.575967     Document Type: Article

References (28)

1. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009;114:5436-5443
2. Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 2009;23:442-448
3. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/ m(2) melphalan and 8 Gy total body irradiation plus 140 mg/ m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735 (Pubitemid 34525530)
4. Fenk R, Schneider P, Kropff M, et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 2005;130:588-594 (Pubitemid 43899763)
5. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009;27:5720-5726
6. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502 (Pubitemid 38010075)
7. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006;132:584-593 (Pubitemid 43381591)
8. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498 (Pubitemid 41007864)
9. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132 (Pubitemid 350146107)
10. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142 (Pubitemid 350146108)
11. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800-807
12. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-3294
13. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788-1793
14. Roussel M, Moreau P, Huynh A, et al. Bortezomib and highdose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32-37
15. Lee CK, Barlogie B, Zangari M, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002;30:873-878 (Pubitemid 36097475)
16. Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006;106:1084-1089
17. Krivanova A, Hajek R, Adam Z, et al. Second autologous transplantation for multiple myeloma patients relapsing after the first autograft and a pilot study for the evaluation of experimental therapy. Report of the prospective nonrandomised pilot study of the Czech Myeloma Group. Bone Marrow Transplant 2004;33:355-355
18. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91:141-142 (Pubitemid 43235400)
19. Elice F, Raimondi R, Tosetto A, et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006;81:426-431 (Pubitemid 43787930)
20. Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417-422
21. Mikhael JR, Zadeh S, Stewart AK, et al. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma. Blood 2009;114(Suppl. 1): Abstract 1217
22. Burzynski JA, Toro JJ, Patel RC, et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009;50:1442-1447
23. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123 (Pubitemid 28435189)
24. Ailawadhi S, Abdelhalim AN, Derby L, et al. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer 2010;116:84-92
25. Fenk R, Hieronimus N, Steidl U, et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006;34:1296-1302 (Pubitemid 44374839)
26. Kobbe G, Bruns I, Schroeder T, et al. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010; 21:1898-1904
27. Chaidos A, Giles C, Auner HW, et al. Second autologous stem cell transplantation is effective salvage therapy for relapsed multiple myeloma. Blood 2009;114(Suppl. 1): Abstract 1229
28. Kumar L, Ghosh J, Ganessan P, Gupta A, Hariprasad R, Kochupillai V. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transplant 2009;43:481-489